Research Article

iTRAQ-Based Quantitative Proteomic Analysis Identified HSC71 as a Novel Serum Biomarker for Renal Cell Carcinoma

Figure 1

Validation of the serum HSC71 by Western blotting. (a) Serum HSC71 level was further examined using Western blotting in 6 additional serum samples from ccRCC patients (R1–R6) and healthy people (H1–H6). (b) Quantification of the densitometric analysis of the Western blotting bands was performed. The average concentration of HSC71 was 2.39-fold () higher in the RCC groups than in the Healthy group.
(a)
(b)